Soleno Therapeutics (SLNO) Cash from Operations (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Cash from Operations data on file, last reported at 25980000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations rose 179.32% year-over-year to 25980000.0 in Q1 2026; TTM through Mar 2026 was 105532000.0, a 218.15% increase from a year earlier, with the FY2025 full-year figure at 46800000.0, up 167.73% from the prior year.
• Cash from Operations for Q1 2026 stood at 25980000.0, down from 48706000.0 in the prior quarter.
• Over the last five years, Cash from Operations for SLNO reached as high as 48706000.0 in Q4 2025 and fell as low as 32752000.0 in Q1 2025.
• Historically, Cash from Operations has averaged 2472764.71 across 5 years, with a median of 6332000.0 in 2023.
• Across the five-year window, Cash from Operations tumbled 279.97% in 2024 and surged 391.4% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 5143000.0 in 2022, then fell by 22.77% to 6314000.0 in 2023, then tumbled by 279.97% to 23991000.0 in 2024, then soared by 303.02% to 48706000.0 in 2025, then sank by 46.66% to 25980000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 25980000.0 in Q1 2026, 48706000.0 in Q4 2025, and 43494000.0 in Q3 2025.